Who are IV Furosemide and PO Metolazone's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/iv-furosemide-and-po-metolazone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

IV Furosemide and PO Metolazone — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

IV Furosemide and PO Metolazone (IV Furosemide and PO Metolazone) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Loop diuretic and thiazide-like diuretic combination. Area: Cardiovascular.

marketed Loop diuretic and thiazide-like diuretic combination Na-K-2Cl cotransporter (NKCC2) and Na-Cl cotransporter (NCC) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

IV Furosemide and PO Metolazone (IV Furosemide and PO Metolazone) — Rambam Health Care Campus. IV furosemide and PO metolazone work synergistically as loop and thiazide-like diuretics to increase sodium and water excretion, reducing fluid overload.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
IV Furosemide and PO Metolazone TARGET	IV Furosemide and PO Metolazone	Rambam Health Care Campus	marketed	Loop diuretic and thiazide-like diuretic combination	Na-K-2Cl cotransporter (NKCC2) and Na-Cl cotransporter (NCC)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Loop diuretic and thiazide-like diuretic combination class)

Rambam Health Care Campus · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). IV Furosemide and PO Metolazone — Competitive Intelligence Brief. https://druglandscape.com/ci/iv-furosemide-and-po-metolazone. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab